and treatment type (including immunosuppressants, corticosteroids, and antifibrotic agents). The study comprised 433 ...

SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic ...

More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

Pliant Therapeutics (PLRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

These compelling results support advancing the development of nintedanib DPI for patients living with IPF, a chronic and progressive fibrotic lung disease with limited treatment options,” said Michael ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

Nashville, Tennessee Friday, November 8, 2024, 13:00 Hrs [IST] ...

CAL101, an investigational therapy with the potential to treat pulmonary fibrosis, showed a favorable safety and pharmacological profile in a Phase 1 clinical trial, according to results announced by ...

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH ...

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...